679 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This comprehensive review underscores that optimizing nutritional support is absolutely essential for maximizing the therapeutic benefits and minimizing potential risks associated with GLP-1 receptor agonist therapies…
This comprehensive review provides a critical, evidence-based framework for clinicians managing Type 2 Diabetes, moving beyond a glucose-centric approach. It underscores the importance of personalized medicine, where …
This comprehensive bibliometric analysis provides a crucial roadmap for understanding the evolving landscape of GLP-1 RA adverse effect research. The findings identify key research hotspots and neglected areas, guidin…
This comprehensive meta-analysis solidifies the role of GLP-1 agonists as highly effective treatments for weight loss and improved body composition in adults with overweight or obesity. The significant reduction in fa…
This comprehensive review provides crucial evidence for clinicians to make informed decisions when prescribing pharmacological interventions for weight management in non-diabetic adults. The significant weight loss ob…
This Mendelian Randomization study provides robust genetic evidence for the causal long-term benefits and safety of GLP-1R agonists and SGLT2 inhibitors extending beyond their current use in high-risk patients. The fi…
This review is crucial for guiding future research and clinical practice in the rapidly evolving landscape of GLP-1 therapies, emphasizing a holistic approach to patient care. Understanding the psychological dimension…
This research strengthens the understanding of metformin's mechanism of action beyond its primary glucose-lowering effects, highlighting its sustained impact on GLP-1, a key hormone for glucose homeostasis and appetit…
This comprehensive real-world data provides crucial insights for clinicians and patients navigating treatment options for Type 2 Diabetes and obesity. The findings underscore Tirzepatide's potential for greater metabo…
While this specific study was terminated without reporting results, the underlying research question remains highly relevant. If completed, positive findings could have highlighted Liraglutide's potential beyond weigh…
If IBI362 demonstrates superior or comparable efficacy with a favorable safety profile against dulaglutide, it could represent a significant advancement in Type 2 Diabetes management. This would provide a new therapeu…
This large-scale registry is crucial for understanding the current state of obesity and Type 2 Diabetes Mellitus management in China, a region with unique dietary and lifestyle factors. The real-world data collected w…
The successful completion of this Phase III trial could establish IBI362 as a novel and effective treatment option for MAFLD, a condition with limited approved pharmacotherapies. Given the high prevalence of MAFLD in …
This Phase 1 study is crucial for the continued development of survodutide, as it provides foundational data on how the drug behaves in a specific ethnic population. Understanding the pharmacokinetics and safety profi…
If the results demonstrate significant and sustained weight loss, survodutide could represent a major advancement in the treatment of obesity and overweight, offering a new, potent therapeutic option. This is particul…
While this specific study did not yield data, the initial intent highlights a critical area of need: understanding how combination therapies like IDegLira perform in real-world settings for patients whose Type 2 Diabe…
Liraglutide is already a cornerstone in managing Type 2 Diabetes and has demonstrated significant cardiovascular benefits, including a 13% reduction in major adverse cardiovascular events in previous trials. This stud…
Understanding the interaction between Liraglutide and clock genes could provide novel insights into the pathogenesis of Type 2 Diabetes and the broader metabolic effects of GLP-1 receptor agonists. This research is cr…
The abstract outlines the study's primary objective to determine the effectiveness and safety of adding GLP-1 agonist therapy to basal insulin. The investigators hypothesized that this combination would lead to statis…
This study provides strong evidence supporting the enhanced efficacy of combining a basal insulin (insulin degludec) with a GLP-1 receptor agonist (liraglutide, a class of drugs that mimic a natural hormone to lower b…
As this PHASE 4 clinical trial is currently RECRUITING participants, specific findings are not yet available, with an estimated completion date of 2026-07-01. Researchers are meticulously collecting data from an estim…
This Phase III clinical trial is crucial because it could validate a new, potentially more accessible or cost-effective semaglutide formulation for obesity treatment. TQF3510 could offer an additional option for patie…
Tirzepatide has already demonstrated significant efficacy, and exploring higher or alternative dosing strategies could further optimize patient outcomes by potentially enhancing glycemic control and weight loss. This …
The successful completion of this Phase 3 trial is a significant milestone, as Tirzepatide (a dual GIP and GLP-1 receptor agonist) has already demonstrated robust efficacy in adults with Type 2 Diabetes and obesity. I…
This research provides compelling evidence that GLP-1 receptor agonists may exert direct cardioprotective effects against atrial fibrillation, extending beyond their well-documented benefits in weight management and g…
This study provides compelling evidence that oral semaglutide offers sustained, comprehensive cardiovascular protection beyond glycemic control and weight loss, significantly reducing the risk of major cardiovascular …
This real-world study provides compelling evidence that treatment persistence is a critical determinant for maximizing the comprehensive benefits of Tirzepatide across the spectrum of Cardio-Metabolic-Kidney Syndrome.…
The substantial and clinically meaningful weight loss achieved with once-weekly Mazdutide positions it as a highly promising therapeutic agent for obesity and overweight. The dual agonism of GLP-1 and GIP receptors ap…
The first approval of Mazdutide in China is a pivotal development, introducing a novel dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist to the therapeutic landscape. This provides a …
This pilot study provides compelling preliminary evidence that liraglutide could offer a novel therapeutic approach for sleep apnea in non-diabetic individuals, potentially independent of its weight-loss effects. The …
This comprehensive evaluation provides critical evidence supporting the superior efficacy of certain long-acting GLP-1 RAs in managing Type 2 Diabetes, particularly concerning glycemic control and weight reduction. Th…
This comprehensive network meta-analysis provides compelling evidence that anti-diabetic agents are not only effective in managing diabetes but also hold significant promise for treating MASH, a condition with limited…
Survodutide's dual agonism represents a significant advancement, offering a multi-faceted approach to treating complex cardiometabolic diseases by simultaneously targeting weight loss, glycemic control, and hepatic st…
Understanding the baseline characteristics of participants in a large Phase 3 trial is crucial for interpreting the future efficacy and safety results, ensuring the findings are generalizable to the target patient pop…
This research boldly underscores the critical role of hepatic GCGR in mediating the profound metabolic benefits of dual GLP-1R/GCGR agonists like survodutide. Understanding this mechanism could lead to the development…
This case report highlights a rare but significant potential adverse effect of semaglutide, suggesting that it might induce hypercapnia even in individuals with healthy lungs. This finding is critical as it expands th…
This research establishes selective amylin receptor agonism as a powerful new therapeutic strategy for metabolic diseases, potentially offering superior benefits over existing incretin-based therapies. The distinct me…
This research highlights critical areas for intervention to optimize patient education and improve outcomes for individuals using Saxenda®. Addressing the identified barriers, such as time constraints and lack of stan…
Optimizing drug formulation is crucial for enhancing patient convenience, adherence, and ultimately, therapeutic efficacy for conditions like obesity and MASH. If Formulation B2 demonstrates superior or comparable bio…
Understanding the specific receptor binding profiles of BI 456906 is a critical first step in evaluating its potential as a novel therapeutic agent for obesity. If BI 456906 demonstrates significant and distinct gluca…
This comprehensive review underscores the immense potential of novel drug targets, innovative drug classes, and cutting-edge technologies to revolutionize the treatment landscape for metabolic diseases. The insights g…
This review provides crucial reassurance for both clinicians and patients regarding the thyroid safety profile of GLP-1 RAs, particularly concerning the previously raised concerns about medullary thyroid carcinoma (MT…
The development of multi-agonist incretin therapies and novel non-incretin pathways represents a critical advancement, offering more potent and comprehensive treatment options for obesity and Type 2 Diabetes than ever…
This Phase 1 study is critically important as it seeks to understand the fundamental metabolic mechanisms of survodutide, a novel therapeutic candidate for obesity. If survodutide demonstrates superior or distinct ben…
This study highlights Dapagliflozin's potential as a valuable adjunctive therapy for Type 1 Diabetes patients struggling with optimal glycemic control despite existing Insulin and Liraglutide regimens. The observed be…